531 related articles for article (PubMed ID: 20028512)
1. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.
Gisslén M; Krut J; Andreasson U; Blennow K; Cinque P; Brew BJ; Spudich S; Hagberg L; Rosengren L; Price RW; Zetterberg H
BMC Neurol; 2009 Dec; 9():63. PubMed ID: 20028512
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C.
de Almeida SM; Ribeiro CE; Rotta I; Piovesan M; Tang B; Vaida F; Raboni SM; Letendre S; Potter M; Batistela Fernandes MS; Ellis RJ;
J Neurovirol; 2018 Feb; 24(1):28-40. PubMed ID: 29063514
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.
Peterson J; Gisslen M; Zetterberg H; Fuchs D; Shacklett BL; Hagberg L; Yiannoutsos CT; Spudich SS; Price RW
PLoS One; 2014; 9(12):e116081. PubMed ID: 25541953
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.
Krut JJ; Zetterberg H; Blennow K; Cinque P; Hagberg L; Price RW; Studahl M; Gisslén M
J Neurol; 2013 Feb; 260(2):620-6. PubMed ID: 23052602
[TBL] [Abstract][Full Text] [Related]
5. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
6. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
[TBL] [Abstract][Full Text] [Related]
7. Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
Brinkmalm G; Brinkmalm A; Bourgeois P; Persson R; Hansson O; Portelius E; Mercken M; Andreasson U; Parent S; Lipari F; Ohrfelt A; Bjerke M; Minthon L; Zetterberg H; Blennow K; Nutu M
Brain Res; 2013 Jun; 1513():117-26. PubMed ID: 23541617
[TBL] [Abstract][Full Text] [Related]
8. Beta amyloid levels in cerebrospinal fluid of HIV-infected people vary by exposure to antiretroviral therapy.
Fields JA; Swinton MK; Soontornniyomkij B; Carson A; Achim CL
AIDS; 2020 Jun; 34(7):1001-1007. PubMed ID: 32073451
[TBL] [Abstract][Full Text] [Related]
9. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
10. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of fluid biomarkers in Alzheimer's Disease.
Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J
Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.
Rosén C; Andreasson U; Mattsson N; Marcusson J; Minthon L; Andreasen N; Blennow K; Zetterberg H
Neuromolecular Med; 2012 Mar; 14(1):65-73. PubMed ID: 22350541
[TBL] [Abstract][Full Text] [Related]
14. Soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment.
Araki W; Kanemaru K; Hattori K; Tsukamoto T; Saito Y; Yoshida S; Takano H; Sakata M; Yokoi Y; Omachi Y; Nagaoka U; Nagao M; Komori T; Tachimori H; Murayama S; Mizusawa H
Aging Clin Exp Res; 2022 Feb; 34(2):341-347. PubMed ID: 34283410
[TBL] [Abstract][Full Text] [Related]
15. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
16. Heteromers of amyloid precursor protein in cerebrospinal fluid.
Cuchillo-Ibañez I; Lopez-Font I; Boix-Amorós A; Brinkmalm G; Blennow K; Molinuevo JL; Sáez-Valero J
Mol Neurodegener; 2015 Jan; 10():2. PubMed ID: 25573162
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
Marksteiner J; Hinterhuber H; Humpel C
Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
[TBL] [Abstract][Full Text] [Related]
19. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
